Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 14/20 | 0.48 |
| ▸ | MC4R | P32245 | 5/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | MC1R | Q01726 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672221 | 0.88 | MC4R (0.51) | SLC2A1MC4RMC5RMC3RMC1R | |
| SCHEMBL11929577 | 0.87 | SLC2A1 (0.55) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL11929576 | 0.86 | SLC2A1 (0.52) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL11929563 | 0.85 | SLC2A1 (0.47) | SLC2A1MC4RMC5RMC3RMC1R | |
| SCHEMBL4669677 | 0.83 | SLC2A1 (0.46) | SLC2A1MC4R | |
| SCHEMBL4671352 | 0.83 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL4669923 | 0.83 | SLC2A1 (0.46) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL11929606 | 0.82 | SLC2A1 (0.54) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL4669886 | 0.82 | MTNR1B (0.47) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL4671517 | 0.80 | SLC2A1 (0.44) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |